The U.S. Agencies Issue New Merger Guidelines
As 2023 came to a close, the Federal Trade Commission (“FTC”) and the Antitrust Division of the Department of Justice (“DOJ”) issued their new Merger Guidelines, which reflect a dramatic shift in the agencies’ prior guidance regarding how they evaluate transactions and identify those that they view to be problematic. As discussed in more detail here and here, the new Guidelines reflect an expansive approach to merger enforcement that is consistent with the agencies’ public statements calling for more enforcement during this Administration.
Does the Agencies’ Aggressive Rhetoric Match Enforcement Levels?
While the agencies have challenged individual transactions based on novel and/or aggressive theories of harm and report high levels of enforcement activity for FY 2022, recently published data suggests that there were fewer merger enforcement actions in 2023 than in any of the previous twenty years.
That said, the agencies’ record has been mixed, particularly with the more novel theories. For example, courts rejected the agencies’ vertical theories of harm in Microsoft/Activision and UnitedHealth/Change Healthcare and the FTC’s potential competition theory in Meta/Within. But the agencies prevailed in three recent decisions: (1) the Fifth Circuit affirmed the FTC’s prohibition of Illumina’s consummated acquisition of Grail; (2) a judge in the Southern District of New York granted the FTC’s motion to enjoin IQVIA’s proposed acquisition of Propel Media (and the merging parties subsequently abandoned the transaction), and (3) a judge in the District of Massachusetts granted DOJ’s motion to permanently enjoin JetBlue from acquiring Spirit Airlines (the parties appealed to the First Circuit but then terminated the transaction).
Since November 2023, the federal government has filed litigation complaints seeking to challenge four transactions. The companies involved in two of those challenges abandoned their deals—John Muir/San Ramon Medical (hospitals) and Sanofi/Maze Therapeutics (pharmaceuticals). The other two deals are in active litigation—Novant/CHS (hospitals) and Kroger/Albertsons (grocery stores).
Read more about trends in merger enforcement levels in recent years here, here, and here.
Increased Procedural Burdens with Extended Investigations and Proposed New HSR Filing Requirements
More generally, the policies and procedures pursued by the agencies have had the effect of increasing the time and expense of merger investigations. This trend will continue with the agencies’ proposed changes to the HSR rules, which would drastically increase the cost, time, and burden of making merger filings. The practical effect of the new rules would be broad—they would impact every company that is a party to a reportable transaction, irrespective of whether it raised any plausible antitrust issues. Read more about the proposed HSR rule changes here.
The number of Second Requests issued by the agencies hit a record high in FY 2021 but returned to a level close to historical averages in FY 2022, despite the number of filings remaining elevated (complete FY 2023 data is not yet available). Regardless, the investigations have become more onerous, searching, and time-intensive than in the past and, in some instances, have resulted in enforcement actions involving non-merger issues, such as for violating the prohibition on interlocking directorates in Section 8 of the Clayton Act. Read more about that Section 8 enforcement action
here.